XBIT XBiotech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XBIT

Price (delayed)

$2.23

Market cap

$67.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

-$47.47M

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 7

XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company’s mission is to rethink the way antibody medicines are discovered and commercialized by ...

Highlights
XBIT's quick ratio has soared by 143% since the previous quarter and by 34% year-on-year
XBiotech's net income has increased by 12% from the previous quarter
XBiotech's EPS has increased by 11% QoQ but it has decreased by 2.3% YoY
The equity has declined by 23% year-on-year and by 3.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xbiotech.com
Peers: QURE AUPH

Key stats

What are the main financial stats of XBIT

XBIT stock price

How has the XBiotech stock price performed over time
Intraday
-0.45%
1 week
-1.76%
1 month
-3.04%
1 year
-23.1%
YTD
-6.69%
QTD
-3.04%

Financial performance

How have XBiotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.41M
Net income
-$40.16M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 13% QoQ but it fell by 7% YoY
XBiotech's net income has increased by 12% from the previous quarter

Price vs fundamentals

How does XBIT's price correlate with its fundamentals

Growth

What is XBiotech's growth rate over time

Valuation

What is XBiotech stock price valuation
P/E
N/A
P/B
0.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
XBiotech's EPS has increased by 11% QoQ but it has decreased by 2.3% YoY
The P/B is 29% lower than the 5-year quarterly average of 0.7
The equity has declined by 23% year-on-year and by 3.8% since the previous quarter

Efficiency

How efficient is XBiotech business performance
XBIT's ROA is down by 28% YoY but it is up by 6% QoQ
The return on equity has declined by 24% year-on-year but it rose by 6% since the previous quarter
XBIT's ROIC is up by 13% QoQ but it is down by 4.8% YoY

Dividends

What is XBIT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did XBiotech financials performed over time
The current ratio has soared by 144% from the previous quarter and by 34% YoY
XBIT's quick ratio has soared by 143% since the previous quarter and by 34% year-on-year
The debt is 100% lower than the equity
The equity has declined by 23% year-on-year and by 3.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.